Tamura, 188 patient HCQ late treatment study: 299% higher mortality [p=0.04] https://c19p.org/tamurah
copied to clipboard
Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies
et al., Diabetology & Metabolic Syndrome, doi:10.1186/s13098-021-00695-8
Retrospective 188 hospitalized patients in Brazil, showing higher risk of mortality with HCQ. Relatively few patients received HCQ. The results are likely subject to confounding by indication with treatment more likely for severe cases, and severity was not used in adjustments. Confounding by time is likely, with declining use of HCQ and improving SOC over the study period.
|
risk of death, 299.0% higher, OR 3.99, p = 0.04, treatment 25, control 163, adjusted per study, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted confounding by indication likely, substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically.
Tamura et al., 13 Jul 2021, retrospective, Brazil, peer-reviewed, 4 authors, study period 10 March, 2020 - 13 November, 2020.
Late treatment
is less effective
is less effective
tamura
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.